1. Home
  2. SCCO vs VRTX Comparison

SCCO vs VRTX Comparison

Compare SCCO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Copper Corporation

SCCO

Southern Copper Corporation

HOLD

Current Price

$188.05

Market Cap

121.3B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$478.59

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCCO
VRTX
Founded
1952
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
EDP Services
Sector
Basic Materials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
121.3B
115.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
SCCO
VRTX
Price
$188.05
$478.59
Analyst Decision
Sell
Buy
Analyst Count
10
27
Target Price
$124.28
$509.17
AVG Volume (30 Days)
1.9M
1.3M
Earning Date
02-11-2026
02-12-2026
Dividend Yield
1.94%
N/A
EPS Growth
25.54
N/A
EPS
4.67
14.22
Revenue
$12,334,600,000.00
$11,723,300,000.00
Revenue This Year
$15.74
$10.93
Revenue Next Year
$6.81
$8.44
P/E Ratio
$39.43
$32.93
Revenue Growth
12.70
10.33
52 Week Low
$72.75
$362.50
52 Week High
$191.22
$519.68

Technical Indicators

Market Signals
Indicator
SCCO
VRTX
Relative Strength Index (RSI) 71.64 62.38
Support Level $174.45 $429.00
Resistance Level $191.22 $472.58
Average True Range (ATR) 6.86 13.74
MACD 1.03 1.07
Stochastic Oscillator 88.22 82.72

Price Performance

Historical Comparison
SCCO
VRTX

About SCCO Southern Copper Corporation

Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: